A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

European Journal of Cancer

Volumn 45, Issue 1, 2009, Pages 174-182

  Chung, Sui Chu ^a   Hammarsten, Peter ^a   Josefsson, Andreas ^a   Stattin, Pär ^a   Granfors, Torvald ^b   Egevad, Lars ^c   Mancini, Giacomo ^d   Lutz, Beat ^d   Bergh, Anders ^a   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cannabinoid receptor; Gleason score; Kaplan Meier analysis; Prostate cancer

Indexed keywords

CANNABINOID 1 RECEPTOR;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR VOLUME;

ADENOCARCINOMA; AGED; AREA UNDER CURVE; CELL MEMBRANE; CELL PROLIFERATION; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECEPTOR, CANNABINOID, CB1; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 57649242673     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.10.010     Document Type: Article

References (35)

1. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
2. Routh J.C., and Leibovich B.C. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo Clin Proc 80 7 (2005) 899-907
3. Graham J., Baker M., Macbeth F., Titshall V., and Guideline Development Group. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 336 7644 (2008) 610-612
4. Bylow K., Mohile S.G., Stadler W.M., and Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer? a conceptual review. Cancer 110 12 (2007) 2604-2613
5. Klotz L. Active surveillance for favorable-risk prostate cancer: who, how and why?. Nat Clin Pract Oncol 4 12 (2007) 692-698
6. Howlett A.C., Barth F., Bonner T., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54 2 (2002) 161-202
7. Fowler C.J. The cannabinoid system and its pharmacological manipulation - a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 20 6 (2006) 549-562
8. Gómez-Ruiz M., Hernández M., de Miguel R., and Ramos J.A. An overview on the biochemistry of the cannabinoid system. Mol Neurobiol 36 1 (2007) 3-14
9. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 10 (2003) 745-755
10. Bifulco M., Laezza C., Pisanti S., and Gazzerro P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Brit J Pharmacol 148 2 (2006) 123-135
11. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., and Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 68 2 (2008) 339-342
12. Flygare J., and Sander B. The endocannabinoid system in cancer - potential therapeutic target?. Semin Cancer Biol 18 3 (2008) 176-189
13. Sarfaraz S., Afaq F., Adhami V.M., and Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65 5 (2005) 1635-1641
14. Melck D., De Petrocellis L., Orlando P., et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 141 1 (2000) 118-126
15. Mimeault M., Pommery N., Wattez N., Bailly C., and Hénichart J.P. Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate 56 1 (2003) 1-12
16. Sánchez M.G., Sánchez A.M., Ruiz-Llorente L., and Díaz-Laviada I. Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells. FEBS Lett 555 3 (2003) 561-566
17. Nithipatikom K., Endsley M.P., Isbell M.A., et al. 2-Arachidonoylglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res 64 24 (2004) 8826-8830
18. Sarfaraz S., Afaq F., Adhami V.M., Malik A., and Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 281 51 (2006) 39480-39491
19. Egevad L., Granfors T., Karlberg L., Bergh A., and Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 89 6 (2002) 538-542
20. Datta M.W., True L.D., Nelson P.S., and Amin M.B. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol 14 6 (2007) 408-418
21. Kallioniemi O.P., Wagner U., Kononen J., and Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Human Mol Genet 10 7 (2001) 657-662
22. Josefsson A., Wikström P., Granfors T., et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 48 4 (2005) 577-583
23. Grimsey N.L., Goodfellow C.E., Scotter E.L., Dowie M.J., Glass M., and Graham E.S. Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal. J Neurosci Meth 171 1 (2008) 78-86
24. Bouaboula M., Rinaldi M., Carayon P., et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214 1 (1993) 173-180
25. Börner C., Höllt V., and Kraus J. Activation of human T cells induces upregulation of cannabinoid receptor type 1 transcription. Neuroimmunomodulation 14 6 (2008) 281-286
26. Galiègue S., Mary S., Marchand J., et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232 1 (1995) 54-61
27. Ruiz-Llorente L., Sánchez M.G., Carmena M.J., et al. Expression of functionally active cannabinoid receptor CB1 in the human prostate gland. Prostate 54 2 (2003) 95-102
28. Tokanovic S., Malone D.T., and Ventura S. Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Brit J Pharmacol 150 2 (2007) 227-234
29. Endsley M.P., Aggarwal N., Isbell M.A., et al. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: location, hydrolysis and 12-lipoxygenase metabolism. Int J Cancer 121 5 (2007) 984-991
30. Shaul Y.D., and Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773 8 (2007) 1213-1226
31. Zheng D., Bode A.M., Zhao Q., et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 68 10 (2008) 3992-3998
32. Endsley M.P., Thill R., Choudhry I., et al. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer 123 6 (2008) 1318-1326
33. Michalski C.W., Oti F.E., Erkan M., et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122 4 (2008) 742-750
34. Xu X., Liu Y., Huang S., et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 171 1 (2006) 31-38
35. Marsicano G., Wotjak C.T., Azad S.C., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 6897 (2002) 530-534